Romosozumab vs bisphosphonate use was not linked to increased CVD risks among patients with osteoporosis, challenging past concerns over its cardiovascular safety.
In the course of evaluating the optimal duration of bisphosphonate treatment the FDA found little benefit of treatment beyond 5 years. [1,2] Moreover, examination of studies where bisphosphonates ...
The US Food and Drug Administration (FDA) has approved Celltrion’s biosimilars referencing Amgen’s bone disease therapy ...
Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in ...
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.
US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva: Jersey City, New Jersey Wednesday, March 5, 2025, 18:00 Hrs [IST] Celltrion, a leadin ...
Babies may be prescribed bisphosphonate to strengthen their bones. The 18 babies in Carroll’s study experienced a range of health issues and early interventions. Two babies died of respiratory ...
All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback